Table 1. Impact of ALK variant on outcomes in selected retrospective trials.
| Study, year | No. of patients | ALK variants subgroups | Treatment | Primary outcome | Difference in outcome? | Reference |
|---|---|---|---|---|---|---|
| Woo, 2015 | 54 | V1/2/others vs. V3a/3b | 1st & 2nd/3rd generation TKIs | 2-year PFS % | Yes | (8) |
| Cha, 2016 | 52 | V1 vs. V2 vs. V3a/b vs. non-EML4 variant | Platinum doublet, pemetrexed, TKIs | ORR, PFS | No | (9) |
| Lei, 2016 | 61 | V1 vs. V3a/3b vs. others | Crizotinib | mPFS | No | (10) |
| Yoshida, 2016 | 35 | V1 vs. non-V1 | Crizotinib | mPFS | Yes | (11) |
| Mitiushkina, 2018 | 64 | V3a/3b/5a/5b vs. others | Crizotinib, ceritinib | mPFS | No | (12) |
PFS, progression-free survival; mPFS, median progression-free survival; ORR, objective response rate; TKI, tyrosine kinase inhibitor.